Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 3/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6559016 | 0.98 | ACP3 (0.44) | ACP3CNR2CXCL8FLT4AKR1C3 | |
| SCHEMBL27691016 | 0.85 | ACP3 (0.47) | ACP3CNR2AKR1C3AKR1C2P2RX7 | |
| SCHEMBL30428161 | 0.84 | AKR1C3 (0.52) | ACP3CNR2CXCL8AKR1C3AKR1C2 | |
| SCHEMBL194437 | 0.84 | AKR1C3 (0.52) | ACP3CNR2CXCL8AKR1C3AKR1C2 | |
| SCHEMBL28969367 | 0.82 | ACP3 (0.45) | ACP3CNR2AKR1C3AKR1C2P2RX7 | |
| SCHEMBL1061610 | 0.81 | ACP3 (0.47) | ACP3CNR2ALDH1A1LMNAGAA | |
| SCHEMBL7471669 | 0.81 | ACP3 (0.44) | ACP3CNR2P2RX7SMN1; SMN2ALDH1A1 | |
| SCHEMBL9321170 | 0.80 | CXCL8 (0.54) | CXCL8LMNA | |
| SCHEMBL8912757 | 0.80 | ACP3 (0.46) | ACP3CNR2AKR1C3ALDH1A1LMNA | |
| SCHEMBL7472384 | 0.80 | ACP3 (0.46) | ACP3CNR2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451156-A4 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1451156-A1 | 4-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | claimed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-2912021-A1 | AGGRECANASE INHIBITORS | Eli Lilly and Company (US) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014066151-A1 | AGGRECANASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-01 | — | — | WO | disclosed |
| CN-101495458-B | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER IP GMBH | 2014-01-29 | — | — | CN | disclosed |
| EP-2635578-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Hengrui (USA) Ltd. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012088411-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PAMLICO PHARMACEUTICAL INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| CN-101891663-A | Preparation method of bicalutamide intermediate | Hangzhou minsheng pharmaceutical group co ltd | 2010-11-24 | — | — | CN | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1606268-A1 | HETEROCYCLIC KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | ACP3 3437/4885CNR2 456/4885CXCL8 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.